chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a nurse refers to an 8 month old patient of unknown gender. The patient's pertinent medical history, drug reactions/allergies, concurrent conditions and concomitant medications were not reported. On 25-AUG-2017 the patient was vaccinated with first dose of ROTATEQ (lot # M025563 expiry date 06-NOV-2017) (dose and frequency were not reported) orally for prophylaxis. On an unknown date in November 2017 the patient was vaccinated with second dose of ROTATEQ (lot # N013884 expiry date 05-DEC-2018) (dose and frequency were not reported) orally for prophylaxis. On 20-FEB-2018 the patient was vaccinated with third dose later than 10 weeks after the second dose of ROTATEQ (lot number N013884 expiry date 05-DEC-2018) (dose and frequency were not reported) orally for prophylaxis. No adverse effects were reported. No product quality complaint involved.
whole face blew up; face became red; face became scaly; This spontaneous case was reported by a consumer and describes the occurrence of FACE INJURY (whole face blew up), ERYTHEMA (face became red) and SKIN EXFOLIATION (face became scaly) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical History).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FACE INJURY (whole face blew up), ERYTHEMA (face became red) and SKIN EXFOLIATION (face became scaly). At the time of the report, FACE INJURY (whole face blew up), ERYTHEMA (face became red) and SKIN EXFOLIATION (face became scaly) outcome was unknown.            No concomitant medication was reported.   Reporter did not allow further contact
(right arm) vomited after shot.  Had a fever, arm red, swollen (4x4 area).
Mild bruising and swelling at injection sight (upper right arm), sore arm,  and severe fatigue  All side effects lasted about 24 hours Treatment: exercise to help soreness and lots of sleep to help the fatigue....I slept about 14 hours!
Cellulitis at injection site with warmth, redness and pain. Continues even today but swelling is going down and it is not as red but it itches.
headache; fever; body aches; joint pain; chills; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache), PYREXIA (fever), MYALGIA (body aches), ARTHRALGIA (joint pain) and CHILLS (chills) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0031321A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Mar-2021, the patient experienced HEADACHE (headache), PYREXIA (fever), MYALGIA (body aches), ARTHRALGIA (joint pain) and CHILLS (chills). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) at an unspecified dose and frequency. At the time of the report, HEADACHE (headache), PYREXIA (fever), MYALGIA (body aches), ARTHRALGIA (joint pain) and CHILLS (chills) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.
Intractable vomiting not alleviated by over the counter medications. Vomiting was reccurrent over a 4 hour time period; no other suspected causes (no unusual food, not pregnant, etc.).
Patient fainted while sitting in a chair after receiving the vaccine. After checking on her, she was responsive and was nervous about receiving the vaccination.
This case was reported by a other health professional via call center representative and described the occurrence of inflammation in a adult patient who received FLUARIX QUADRIVALENT (batch number 29PD2, expiry date unknown). In September 2016, the patient received FLUARIX QUADRIVALENT. In September 2016, less than a week after receiving FLUARIX QUADRIVALENT, the patient experienced inflammation, tenderness and swelling. On an unknown date, the outcome of the inflammation, tenderness and swelling were unknown. It was unknown if the reporter considered the inflammation, tenderness and swelling to be related to FLUARIX QUADRIVALENT. Additional details were reported as follows: The reporter explained that several staff, about 8, who received the FLUARIX QIV vaccine had developed large amounts of inflammation, swelling and tenderness. On the date of reporting, it was the day 4 after injection. No further details were reported. On 30th September 2016 at 3:14 hours, the reporter's office was contacted and got voicemail that they contacted GlaxoSmithKline GMS Quality and found FLUARIX in Lot Locator system. This was one of the 8 cases reported by the same reporter.
erythema, ecchymosis, pain & edema @ inject site are reported in a pt who recvd 1 dose of flu vax; above sx occurred 12 hrs p/flu vax given & resolved w/in 48 hrs;
PATIENT RECEIVED PFIZER 5-11YR MONOVALENT BOOSTER AFTER 10/12/2022. NO ADVERSE REACTIONS
Tachycardia (checked on my night shift and at home frequently Saturday night into Sunday.) Bpm = 105 throughout random checks.  Fatigue  Heart flutters
High fever for three days, followed by body rash, beginning 06/19-still has it today 06/24.
I had bronchitis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: BRONCHITIS (non-serious), outcome "unknown", described as "I had bronchitis". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: It was reported that, patient went home today (at the time of reporting) and found out his wife was positive. She had both Pfizer shots he had both Pfizer shots, A week and a half ago he was negative for covid 19. What the hell we gonna do now. He had bronchitis. Now what do he do. Should he go back to the clinic tomorrow to get retested? Do he need extra medications? They got some stuff that takes the crap out of his lungs waiting for that to come in. He can't believe this. He told her to not to get stressed about it. Sick of the bologna. He still wear my mask, stuff on his hands.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report as received from a physician via a company representative refers to an adult male patient in his 50's. Information regarding relevant medical history and concomitant condition were not reported. Approximately on an unknown date in 2013 (reported as "2 years ago"), the patient was vaccinated with ZOSTAVAX (dose, route, lot # not reported). Information regarding concomitant medications was not reported. It was reported that the patient broke out in a mild shingles like rash shortly after receiving ZOSTAVAX (onset date unspecified). The outcome of the event was unknown. Additional information is not expected because we are not allowed to contact the physician.
Case number PHEH2015US002081 is an initial spontaneous report received from a consumer on 27 Jan 2015 and a follow up report from the physician received on 19 Feb 2015. This report refers to a 56 years old female patient. She had good overall health. Her concomitant medications were not reported. She was vaccinated with one dose of FLUVIRIN (batch number: 1411901, expiry date: May 2015) at a dose of 0.5 ml intramuscularly in the left deltoid on 30 Oct 2014. It was reported that she experienced rash in early-mid November and she had rash all over on 10 Nov 2014. It sometimes changed location and her back was covered with rash. She stated that the rash itched terribly. Upon follow up, the physician stated that the patient did not report any rash to them, but if she did have any, the physician asked to consider them as an allergic reaction. The outcome of event was reported as condition unchanged. The consumer reported the event as serious (disabling). The causality of the events was not reported. Follow up report from the physician received on 19 Feb 2015: Changed product coding from seasonal influenza vaccine to FLUVIRIN. Added batch number, expiry date, site of vaccination and dose of FLUVIRIN vaccine.
Information has been received from a healthcare professional from a literature report. A previously healthy 33-year-old male was referred to reporters retina service for sudden onset of intermittent floaters and flashing lights in his right eye which developed. 3 weeks following inactivated hepatitis A (manufacturer unknown), yellow fever, and typhoid vaccinations. These vaccines were given prophylactically in preparation for a 2-week trip. The patient had previously received one dose of hepatitis A vaccine (manufacturer unknown) 12 years prior (he did not complete the series) and had never before been exposed to typhoid or yellow fever immunizations. On examination, visual acuity was 20/20 in both eyes. Pupil responses, visual fields to confrontation, and intraocular pressures (14 mmHg) were normal bilaterally. Slit lamp examination revealed 1 +anterior vitreous inflammation bilaterally. Fundus examination of the right eye revealed a few scattered peripheral nonpigmented chorioretinal lesions. The macula and optic nerve appeared normal, and the left fundus was unremarkable. Fluorescein angiography of the right eye demonstrated scattered peripheral hyperfluorescent lesions correlating with those seen in the fundus, and there was no evidence of disc leakage. A comprehensive review of systems was negative for fever, rash, oral ulcers, arthralgias, headache, or vertigo. There was no history of autoimmune disease or recent viral illness. There was no family history of autoimmune disease. The patient was diagnosed as having acute multifocal choroiditis and observed. After 2 weeks, the patient continued to describe occasional floaters. His ocular examination revealed continued low grade anterior vitreous inflammation and the peripheral retinal lesions began to demonstrate early hyperpigmentation. Because of the nonprogressive examination findings and given the excellent visual acuity, it was decided to continue close observation. At 8 weeks, the patient's symptoms had resolved, the vitreous was clear of cellular inflammation, and the fundus revealed punched out areas of retinal pigment epithelium atrophy. Although this case did not prove causation and the relationship remains presumptive, it did suggest that some vaccinations can act as a trigger for immunologic initiation that could subsequently lead to the development of noninfectious uveitis. Additional information has been requested.
I had minimal symptoms at time of shot. My arm was sore for a few days and I was pretty tired. But 12 days later my arm has begun to swell, it is warm to the touch, and is red all around the area where the vaccine was injected.
Involuntary uncontrollable bowel incontinence.  ( one time  no stomach cramp or warning)
Headache & Myalgia Narrative:  dose 1- day 1 sore arm dose 2- day 1-3 -  Fatigue, body soreness, headache.
2/1/16 Brought in for evaluation of rash on (L) thigh. Foster mom states 1-2 days after vaccines he developed a knot on left thigh and rash that was generalized - more focused on left thigh. Resolved with symptomatic care.
This spontaneous report has been received from a male patient of unknown age referring to himself. On an unknown date the patient was vaccinated with PNEUMOVAX 23 (dose, route and lot# not reported). The patient reported that the patient had been getting the PNEUMOVAX 23 every few years (dates were not specified). The patient stated that he had received the PNEUMOVAX 23 a total of 5 times. The patient stated that every few years he got revaccinated with various vaccinations including the PNEUMOVAX 23. Additional information is not expected as there is no contact information.
pt recv vax 13FEB96 & pt devel a full blown case of varicella w/vesicles all over the body;pt varicella persisted
The patient woke up at around 0230 on 5/11/21 with aphasia, right sided weakness and facial droop. He was immediately brought to the ER and after CT was given tenecteplase.
admitted  for shock liver and COVID-19 infection. Treatment for COVID was not indicated as patient did not have any significant symptoms or hypoxia; Tx: Eliquis x2 days, then lovenox, doxycycline, singulair,  improved over the next 3-4 days, with LFTs coming down each day. However, on 02/01, patient persistently hypotensive despite multiple IV fluid boluses. Her RBC dropping, so blood transfusion was ordered; condition continued to deteriorate, transferred to ICU requiring pressors; intubated and MTP was initiated as she continued to have dropping blood count despite blood transfusion. Stat CT abd/pelvis showed a large retroperitoneal hematoma. Initial CT abd/chest done 3 days prior had been unremarkable with no signs of bleeding. She was evaluated by IR to assess for possible embolization, however access to the bleed was not possible. Family eventually changed patient's code status to DNR. family decided on withdrawal of care. Patient passed away shortly afterwards.
edema; This spontaneous case was reported by a patient and describes the occurrence of OEDEMA (edema) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OEDEMA (edema). At the time of the report, OEDEMA (edema) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information was not provided by reporter.
redness around the injection site; itchiness around the injection site; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE PRURITUS (itchiness around the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included OMEPRAZOLE for an unknown indication.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, the patient experienced INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE PRURITUS (itchiness around the injection site). At the time of the report, INJECTION SITE ERYTHEMA (redness around the injection site) and INJECTION SITE PRURITUS (itchiness around the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No treatment information was reported.
Pt was given Moderna Bivalent Booster vaccine (0.25ml) instead of Moderna (6m-5y) monovalent vaccine.  Pt's mother reports no adverse reactions as of 11/15/2022
Information has been received from a licensed practical nurse concerning unspecified number of patients of unknown age or gender. There was no information about concurrent condition, medical history or concomitant therapy. On unspecified dates, the patients received doses of improperly stored VARIVAX (dose and route not provided, lot # included: L000455 with expire date 06-JAN-2017 and L017142 with expire date 13-MAY-2017). No adverse effect was reported. Additional information has been requested.
At 1 am the morning after the second injection I had severe body aches uncontrollable shaking and chills , fever headache and nausea . This lasted about two days I felt fine on that Saturday after the shot on wed. On Sunday I stated with a sore throat , Sinus congestion, headache ,  strange rash under my left arm and had malaise . The respiratory symptoms lasted a week and now I am very fatigued , headache neck and should pain and a fever blister on my bottom lip. I had chicken pox when I was a child. I have had fever blisters on lip before
PT. received HPV dose #1 on 04/16/14 approximately 3 wks after developed s/s of back/chest pain and decreased urination as reported to dr on 7/14/14 at OV for same S/s approximately 3 weeks after HPV #2 was given. Pt. sent for CXR and AXR (KUB). All WNL. Dr suspects reaction to HPV vaccines.
Mom reports child developed urticaria 2 days after vaccine. Child was taken to ED for evaluation of hives but at time of arrival rash was gone. He was prescribed benadryl. Otherwise asymptomatic.
ATTEMPTED TO GIVE PATIETN VACCINE WHILE PATIENT APPEARED RELATIVELY CALM AND SEATED APPROPRIATELY. PATIENT SUDDENLY MOVED DUE TO DISTRESS WHEN NEEDLE WAS INSERTED.  DUE TO PATIENT MOVEMENT NEEDLE CAME OUT BEFORE I COULD ADMINISTER CONTENTS OF SYRINGE. INADVERTENTLY POKED MYSELF WITH USED NEEDLE.
TDAP administered on 5/26.  Swelling and redness locally at injection site.  Reaction was not immediate and occurred 24 or more hours later.  No systemic sx, no fever, lip, face, or throat swelling; no wheezing.  Mild/Moderate severity.
Patient complained of sore arm and at later date (11-23-18) says was diagnosed with shingles; received Tx of Acyclovir 800mg 5x day x 10d. Today 4-4-19 says arm still sore.
My newborn son experience a large stroke that destroyed 1/4 of his brain and a smaller stroke.  The first indication something was wrong was that he began having seizures after the immunization.
Pain at injection site- 4 days, headache -still going and blurry vision- still going
Basic paralysis within five days. Worsening neurological symptoms since. Now permanently disabled due to host of mental and physical problems. Still seeking answers and treatment.
big black and blue mark where they gave me the shot,  I don't know if its from me taking off the bandage.; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient) reported that a female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot and expiry were not reported), via an unspecified route of administration on an unspecified date as 1 st dose, single for covid-19 immunisation. Medical history included cancer. The patient's concomitant medications were not reported. The patient got her first dose of vaccine "on the 3rd or 4th" (did not verify date before disconnecting call). Second dose was scheduled for 04March2021. After the first dose (on an unspecified date), she has big black and blue mark where they gave her the shot, she didn't know if its from her taking off the bandage. The patient took warfarin sodium (COUMADIN), "no pain with it at all". Asked if that was from the vaccine. The patient asked if she could get her "lung cancer shot" and the vaccine the following day. The patient did not know the lung cancer injection medication name or type. The patient's son that lived with her, tested positive for covid without symptoms. Asking, "could I get covid after vaccine? First dose?" Also asked if a person, who unknowingly has covid and got dose, if it would be safe or cause issues. Further asked if someone gets covid infection after the vaccine, if that would mean it didn't protect them. The patient stated, "why is it recorded where we are talking over each other-its driving me nuts. Its a shot in dark". The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Woke up at 600am w/ onset of epigastric discomfort.  Patient states discomfort radiated to L flank, intra-scapular region.   Final diagnoses Pericarditis.  3 months of colchicine
Adverse reaction; A spontaneous report was received from a consumer concerning a  patient of unknown age and gender who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events adverse reaction.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On unknown date, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: UNKNOWN) via unknown route for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the event(s) Adverse reaction.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), adverse reaction was unknown.; Reporter's Comments: Very limited information regarding this event has been provided at this time.  Further information has been requested.
Severe soreness at injection site for two days. Pain in hip for two days. Tinnitus in left ear starting several days after shot and still persisting
D68.9 COAGULOPATHY, UNSPECIFIED TYPE 9/16/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE G62.9 PERIPHERAL NEUROPATHY 3/12/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE I95.9 HYPOTENSION 7/20/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE J96.00 ACUTE RESPIRATORY FAILURE 7/27/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE R57.0 CARDIOGENIC SHOCK 9/16/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE D68.9 COAGULOPATHY, UNSPECIFIED TYPE 9/16/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA    VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE G62.9 PERIPHERAL NEUROPATHY 3/12/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA    VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE I95.9 HYPOTENSION 7/20/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA    VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE J96.00 ACUTE RESPIRATORY FAILURE 7/27/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA    VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE R57.0 CARDIOGENIC SHOCK 9/16/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA    VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE D68.9 COAGULOPATHY, UNSPECIFIED TYPE 9/16/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE G62.9 PERIPHERAL NEUROPATHY 3/12/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE I95.9 HYPOTENSION 7/20/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE J96.00 ACUTE RESPIRATORY FAILURE 7/27/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE R57.0 CARDIOGENIC SHOCK 9/16/2021 VENTRICULAR TACHYCARDIA, UNSPECIFIED TYPE D68.9 COAGULOPATHY, UNSPECIFIED TYPE 9/16/2021 VENTRICULAR TACHYCARDIA, NONSUSTAINED G62.9 PERIPHERAL NEUROPATHY 3/12/2021 VENTRICULAR TACHYCARDIA, NONSUSTAINED I95.9 HYPOTENSION 7/20/2021 VENTRICULAR TACHYCARDIA, NONSUSTAINED J96.00 ACUTE RESPIRATORY FAILURE 7/27/2021 VENTRICULAR TACHYCARDIA, NONSUSTAINED R57.0 CARDIOGENIC SHOCK 9/16/2021 VENTRICULAR TACHYCARDIA, NONSUSTAINED